Jason A. Efstathiou

3 weeks ago | europeanurology.com | Alberto Briganti |Vita-Salute San Raffaele |Jason A. Efstathiou |Ribeirão Preto

aDepartment of Radiological Sciences, Oncology and Pathology, Sapienza University of Rome, Rome, Italy bUnit of Urology/Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy cDepartment of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA dDepartment of Radiology, Heersink School of Medicine, University of Alabama, Birmingham, AL, USA eDepartment of Radiology, Columbia...

Sep 30, 2024 | urotoday.com | Jason A. Efstathiou

Read the Full Video TranscriptE. David Crawford: Hi, everyone. This is E. David Crawford. Just recently we've had the opportunity to talk with Dr. Jason Efstathiou, who is a professor of radiation oncology at Harvard, about a clinical trial called the PARTIQoL trial. It's a Phase III trial comparing proton beam therapy to IMRT for localized prostate cancer. He highlighted the potential benefits of proton therapy and challenges of conducting comparative studies.

Sep 27, 2024 | urotoday.com | Jason A. Efstathiou

Read the Full Video TranscriptE. David Crawford: Hi, everyone. My name is E. David Crawford. We had the opportunity to talk with Dr. Jason Efstathiou from Harvard. He's a radiation oncologist, about a trial called the PARTIQoL Trial, a Phase III study comparing proton beam therapy to IMRT for localized prostate cancer. He highlighted the potential benefits of proton therapy and the challenges of conducting comparative studies.

Apr 11, 2024 | onclive.com | Jason A. Efstathiou

April 11, 2024Jason Efstathiou, MD, DPhil, discusses the utility of trimodal therapy in patients with muscle-invasive bladder cancer.

Mar 15, 2024 | onclive.com | Jason A. Efstathiou

Jason Efstathiou, MD, DPhil, radiation oncologist, professor, radiation oncology, Harvard Medical School; vice-chair, Faculty & Academic Affairs, director, Genitourinary Service, Department of Radiation Oncology; clinical co-director, The Claire and John Bertucci Center for Genitourinary Cancers, Massachusetts General Hospital, discusses the current and potential role for tri-modality therapy (TMT) in patients with muscle-invasive bladder cancer (MIBC).